Skip to main content

Together we are beating cancer

Donate now
  • Policy & Insight

Could multi-cancer tests help GPs spot cancer?

by Jessica Lloyd , Sowmiya Moorthie , Samantha Harrison | In depth

19 February 2025

1 comment 1 comment

This photo shows a GP on the phone in his office.
Photo by Patrick Harrison

Most people with cancer are diagnosed after they start experiencing symptoms, which are usually vague and hard to link to a specific cause. Typically, they’ll discuss those symptoms with their GP, who may only have a short appointment to work out what they might mean and decide on the best course of action.   

That’s a tough job. GPs are crucial to the earlier diagnosis of cancer, but they have to deal with a lot of uncertainties. The main problem is that the many potential signs and symptoms of cancer don’t usually point to cancer. Even when they do, it’s hard to tell which type of cancer might be causing them, so picking the right specialist referral route can be a challenge.   

There aren’t currently many tools suited to helping GPs make these decisions. For the third article in our ongoing series, we’re looking at whether multi-cancer tests (MCTs) could change that.  

As we have discussed in previous articles, the emergence of MCTs represents an exciting opportunity to improve diagnosis and care for cancer patients across the pathway. Samples such as blood or urine could be tested for novel markers of many cancers to indicate if and where cancer is present. 

In primary care specifically, MCTs could help GPs make informed decisions about which people with potential cancer symptoms should be referred for urgent cancer investigation.  

As a result, MCTs could help GPs detect more cases of cancer earlier, which has the potential to improve outcomes and reduce cancer-related mortality. Equally, by making it easier to identify people who are unlikely to have cancer, MCTs could also help GPs find the true underlying cause of their symptoms more quickly – saving patients time and stress while reducing the burden on the NHS.  

Multi-cancer tests could help GPs to detect cancer earlier, before symptoms become more overt, and help to get the right people to the right tests quicker. This could really help with rarer cancers and those difficult to detect without invasive tests.

- Dr Katie Elliot, Cancer Research UK GP

In previous articles we have taken a closer look at what MCTs and multi-cancer early detection tests (MCEDs) are, as well as the specific ways MCEDs could be used as part of screening programmes. Now, we’re exploring how MCTs could be used to help support primary care doctors in assessing and managing suspected cancer symptoms.

How are cancers managed in primary care?

GPs are usually the first health professional people present to with symptoms. It’s up to them to rapidly assess whether or not a patient’s list of symptoms could indicate cancer, usually in a short appointment. They make their decisions based on both nationally agreed guidelines and their clinical judgement.  

The guidelines GPs use set thresholds for urgent cancer referral using the probability that a person exhibiting a particular symptom or combination of symptoms actually has cancer. Some of these guidelines include abnormalities in routine blood tests, most of which are not specific for cancer but could indicate an increased risk of cancer when combined with signs and symptoms.  

There are also a small number of triage tests used in primary care that support assessment of cancer risk. These tests help GPs identify which patients with signs and symptoms of cancer should be referred urgently for further investigation by a specialist and which ones they can safely monitor themselves. However, for many cancers, there is no triage test, or the available test is poor.  

After a patient is referred, further investigations by specialists in secondary care either rule out cancer or lead to a cancer diagnosis.  

The challenge  

The challenge for GPs is that signs and symptoms are generally poorly predictive for cancer. 

Some cancer signs and symptoms are specific (for example a breast lump indicating breast cancer). These are known as ‘red flag’ or ‘alarm symptoms’ and are associated with a higher risk of cancer. But evidence suggests that over 50% of patients subsequently diagnosed with cancer do not initially present to their GP with alarm symptoms. Instead, they present with non-specific symptoms (NSS).  

Non-specific symptoms include weight loss, fatigue, abdominal symptoms like pain and bloating, nausea and vomiting, loss of appetite, and non-specific pain such as bone pain. Unlike alarm symptoms, which are usually closely associated with a specific type of cancer, these signs and symptoms could be caused by a range of different cancers or other non-cancer conditions. This presents a challenge as the guidelines often ask GPs to refer patients for investigations to see if they have cancer at a specific site.  

People with NSS are more likely to have multiple visits to the GP and more primary care tests before referral, prolonging the time it takes to reach a diagnosis. While some GPs might still investigate or refer based on their clinical judgement or gut feeling, NSS often don’t meet the threshold for referral laid out in clinical guidelines. As such, people presenting with NSS are more likely to be diagnosed at a later stage or via emergency presentation at a hospital compared to those presenting with alarm symptoms. 

New referral pathways have been created across the UK for patients with non-specific but concerning symptoms of cancer. These pathways recognise that NSS can be associated with many cancer sites, and that the risk someone with NSS has cancer is higher when you consider all those possible cancer sites together. This helps provide a more managed route for patients who do not experience alarm symptoms but are still at an increased risk for cancer. Although these pathways have helped establish a way of investigating cancer broadly across multiple sites, GPs must still make an informed decision for which patients with NSS require urgent investigation.  

At the same time, only about 3% of people with red flag symptoms and less than 7% of people referred to NSS pathways have cancer. This is because the bar, or threshold, for referral in national guidance is relatively low (around a 5% probability of cancer).  

The threshold is kept low to ensure that as many people as possible have their cancer diagnosed early, but it creates a capacity challenge. With diagnostic services under immense strain across the NHS, we need new tools to help GPs assess cancer risk and make more informed decisions about who to refer for urgent suspected cancer. 

Multi-cancer tests could support GP decision-making. The additional information they provide could enable more accurate referrals for urgent cancer investigation and tell GPs which cancers to investigate for when a patient’s symptoms could be caused by many different types of cancer.

- Dr Brian Nicholson, GP and Associate Professor

How could multi-cancer tests be used in primary care? 

As described in our previous article, an MCT is a minimally invasive test that uses liquid biopsy technology to search for markers of multiple cancers in a single sample, typically blood, urine, breath, or stool.  

In primary care specifically, MCTs could play an important role in reducing delays, first between a patient seeing their GP with symptoms and being referred for cancer investigation, and then between the referral and the eventual diagnosis. That means they could help the health service diagnose cancer earlier, which is associated with better outcomes, especially for people with fast-progressing cancers.  

When we consider the sheer number of GP appointments per day where people could present with potential cancer symptoms, it’s easy to see how much value MCTs could bring. They could help under-pressure GPs triage patients and optimise referrals, improving patient experience and health system efficiencies.

For example, MCTs could help GPs: 

  • Identify a higher risk of cancerMCTs could give GPs confidence that they are referring the right people, even when they don’t have a red flag symptom to guide them.  
  • Indicate which cancer pathway or investigation to refer them toMCTs could be used alongside or instead of other diagnostic tests to help GPs identify the most appropriate cancer site to investigate. Alternatively, for NSS pathways, they could help to streamline follow-up diagnostic tests.  
  • Identify those with a very low/no risk of cancer – A vast majority of patients who present at their GP do not have cancer. MCTs could help rule out cancer for these individuals, meaning they can be directed towards the most appropriate non-cancer investigations or work with the GP to continue to monitor their symptoms. This would improve patient experience by reducing invasive procedures and anxiety, as well as reducing strain on specialist services. 

It’s not only primary care that could potentially benefit from MCTs. Specialists could also use MCTs to triage and prioritise urgent suspected cancer referrals they get from GPs.  

Using a blood test to detect cancer is often more acceptable to people than having invasive tests. Multi-cancer tests would help GPs to find the right people who need hospital tests.

- Dr Katie Elliot

What evidence do we have about GPs using MCTs? 

There are many different MCTs in development that use different underpinning technologies to detect signals of cancer. These tests have shown that they are capable of detecting cancer in people that have already been diagnosed. However, there is limited evidence of how MCTs would perform in undiagnosed people with symptoms of cancer – and no evidence from a primary care setting.   

There is one completed UK study, called SYMPLIFY, that evaluated the feasibility and performance of GRAIL’s Galleri MCT in symptomatic patients who had been referred for cancer investigation in England and Wales. The authors concluded that if the test was used by GPs in primary care, it could potentially: 

  1. Support GP referral for further cancer investigation if the test was positive
  2. Support a GP decision to monitor the patient and not refer for cancer investigation if the test was negative. 

This means that GPs could use MCT results to help them decide whether to refer patients for suspected cancer, which may lead to a reduction in diagnostic delays. This might indirectly help improve cancer outcomes by allowing cancer treatment to start sooner. 

While these initial results are promising, research is still at an early stage. We need to see more studies of MCTs in primary care to determine performance and cost effectiveness for each of the potential use cases. The good news is that it will be quicker and easier to gather the evidence needed to implement MCTs in primary care. This is because there are already clear pathways where MCTs can be added in and assessed.  

What’s next? 

GPs should have easy and timely access to diagnostic tests that help them identify people who may have cancer. MCTs have potential, but the current model of care will need to change to accommodate them.  

We don’t yet how MCTs might best complement diagnostic pathways in the UK, or which MCTs will be best suited for primary care. We need studies that will measure and support comparisons of different technologies in this space. Such studies would help to generate evidence of: 

  • clinical performance and effectiveness of MCTs in primary care for symptomatic patients 
  • which use case of MCTs for symptomatic patients would be most impactful 
  • the practical implementation and feasibility of MCTs (ie how MCTs can be implemented effectively)
  • how MCT technology can be further developed and optimised for the selected use case(s) 

This evidence is vital to help determine which MCTs offer the most value at specific points in the cancer pathway. We also need to see long-term investment in staff and equipment to test, use and improve MCTs. Over time, this research would support the NHS to make evidence-based decisions about whether, when and how to roll specific MCTs out across the UK. We’re optimistic about the future of MCTs in primary care, but there is still a lot of work to do generate the evidence we need to use them safely and correctly.  

    Comments

  • Rebecca
    28 February 2025

    I think these are a great idea because gps consistently dont listen to patients. I told my dr yesterday i had a new big lump in my neck and that i had lost a stone since xmas. and he said i was not to worry as I showed no big signs like weight loss. I had literally just told him i had lost a stone in less than 8 weeks. They dont listen and we can’t challenge that or we risk having problems with thm in the future.

Tell us what you think

Leave a Reply

Your email address will not be published. Required fields are marked *

Read our comment policy.

    Comments

  • Rebecca
    28 February 2025

    I think these are a great idea because gps consistently dont listen to patients. I told my dr yesterday i had a new big lump in my neck and that i had lost a stone since xmas. and he said i was not to worry as I showed no big signs like weight loss. I had literally just told him i had lost a stone in less than 8 weeks. They dont listen and we can’t challenge that or we risk having problems with thm in the future.

Tell us what you think

Leave a Reply

Your email address will not be published. Required fields are marked *

Read our comment policy.